-
Mashup Score: 8
Chimeric Antigen Receptor T-cell (CAR T-cell) therapy is an effective treatment for relapsed/refractory (R/R) large B cell lymphoma (LBCL). However, patients with central nervous system (CNS) lymphoma were excluded in most of the CAR T-cell therapy trials. This meta-analysis assesses the efficacy with CAR T-cell therapy in LBCL patients with CNS involvement. Two reviewers independently searched PubMed and Cochrane Library to identify all published literature associated with United States Food and Drug Administration approved CAR T-cell therapies for LBCL.
Categories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Letter to the Editor: The Dark Side of CAR-T | ASH Clinical News | American Society of Hematology - 7 month(s) ago
In her May 2023 Editor’s Corner, Brea Lipe, MD, discussed the dark side of chime ric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM). Given their high and durable response rates, there has been much excitement around the use of idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), though various challenges have hindered widespread implementation of these therapies. Here, a reader continues the conversation, raising questions about whether patients with MM should
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy - 9 month(s) ago
Most patients with multiple myeloma experience disease relapse after treatment with a B-cell maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for patients treated with sequential BCMA-TT are limited. We analyzed clinical outcomes …
Source: www.ncbi.nlm.nih.govCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial - 9 month(s) ago
Advances in Therapy – Patients with triple-class exposed relapsed/refractory multiple myeloma (RRMM) have poor outcomes with substantial healthcare costs. Idecabtagene vicleucel (ide-cel), a B-cell…
Source: link.springer.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy - PubMed - 10 month(s) ago
The APRIL CAR was well tolerated, but the clinical responses observed in AUTO2 were disappointing. Subsequently, when comparing the APRIL CAR to other BCMA CARs, we observed in vitro functional deficiencies due to reduced target binding by cell-expressed ligand.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Job Finder - Karriereportal - Universitätsklinikum Essen - 10 month(s) ago
Finden Sie eine Stelle am Universitätsklinikum Essen
Categories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 0Elucidating novel targets in solid tumors for CAR T-cell therapy - 11 month(s) ago
Benjamin Schlechter, MD, Dana-Farber Cancer Institute, Boston, MA, comments on challenges in developing CAR T-cell therapies for solid tumors. Finding…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Earlier Use of CAR T Cells Holds Promise in Blood Cancers, but Access Remains an Issue - 11 month(s) ago
A panel of experts at the American Society of Clinical Oncology Annual Meeting presented the latest research and equity considerations for chimeric antigen receptor (CAR) T-cell therapy in hematological cancers.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 0Wolters Kluwer Health - 11 month(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Bridging Therapy Responses Boost CAR-T Outcomes in LBCL | ASH Clinical News | American Society of Hematology - 12 month(s) ago
Skip Nav Destination April 26, 2023 Thomas R. Collins is a medical journalist based in West Palm Beach, Florida. Achieving a complete response (CR) or partial response (PR) to bridging therapy is associated with better outcomes…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
Chimeric Antigen Receptor T - Cell Therapy for Large B-Cell Lymphoma Patients with Central Nervous System Involvement, a Systematic Review and Meta-analysis - Clinical Lymphoma, Myeloma and Leukemia https://t.co/EEjMP3jNP0 #CAR-T